IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

Company Overview

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies. This platform supports the rapid progression of drug candidates from target validation through early clinical development. IDEAYA has entered strategic collaborations with established pharmaceutical partners to expand the reach of its synthetic lethality portfolio, leveraging complementary expertise in drug discovery, development, and commercialization.

Founded in 2016 and headquartered in South San Francisco, California, IDEAYA maintains research operations in the United States and collaborates with leading academic institutions and industry organizations worldwide. The company’s management team comprises experienced biopharmaceutical executives and oncology researchers who guide its mission to deliver precision medicines to patients with high-need cancers. IDEAYA continues to build on its scientific foundation to bring forward innovative treatments that address genetically defined subsets of tumors.

Key Stats

• Today's Range: $27.83 to $28.79
• 50-Day Range: $28.05 to $35.08
• 52-Week Range: $16.82 to $39.28
• Volume: 877,335 shs
• Average Volume: 1.74 million shs
• Market Capitalization: $2.53 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.44
• Consensus Rating: Moderate Buy

IDEAYA Biosciences Stock Analysis - MarketRank™

IDEAYA Biosciences scored higher than 75% of companies evaluated by MarketBeat, and ranked 154th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 15 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

IDEAYA Biosciences has a consensus price target of $50.44, representing about 75.5% upside from its current price of $28.74.

Amount of Analyst Coverage

IDEAYA Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IDEAYA Biosciences are expected to grow in the coming year, from ($3.97) to ($3.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IDEAYA Biosciences is -17.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IDEAYA Biosciences is -17.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IDEAYA Biosciences has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.34% of the float of IDEAYA Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IDEAYA Biosciences has a short interest ratio ("days to cover") of 4.53.

Change versus previous month

Short interest in IDEAYA Biosciences has recently increased by 8.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IDEAYA Biosciences does not currently pay a dividend.

Dividend Growth

IDEAYA Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.11

News Sentiment

IDEAYA Biosciences has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for IDEAYA Biosciences this week, compared to 5 articles on an average week.

Search Interest

6 people have searched for IDYA on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $1,648,000.00 in company stock, which represents 0.0653% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, IDEAYA Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,648,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.50% of the stock of IDEAYA Biosciences is held by insiders.

Percentage Held by Institutions

98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IDYA Stock Analysis - Frequently Asked Questions

How have IDYA shares performed this year?

IDEAYA Biosciences' stock was trading at $34.57 at the start of the year. Since then, IDYA stock has decreased by 16.9% and is now trading at $28.74.

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its quarterly earnings results on Tuesday, May, 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by $0.10. IDEAYA Biosciences's revenue was down 39.4% compared to the same quarter last year.

When did IDEAYA Biosciences IPO?

IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

Who are IDEAYA Biosciences' major shareholders?

Top institutional investors of IDEAYA Biosciences include Candriam S.C.A. (1.26%), Pictet Asset Management Holding SA (0.82%), Jennison Associates LLC (0.29%) and Bank of New York Mellon Corp (0.28%). Insiders that own company stock include Yujiro S Hata, Jeffrey Stein, Briseno Andres Ruiz, Paul A Stone, Michael Anthony White and Jason Throne.
View institutional ownership trends.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/06/2026
• Bank of America Global Healthcare Conference 2026: 5/13/2026
• Stifel 2026 Targeted Oncology Virtual Forum: 5/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IDYA
• CIK: 1676725
• Web: www.ideayabio.com
• Phone: (650) 443-6209
• Fax: N/A
• Employees: 80
• Year Founded: 2015

Price Target and Rating

• Average Price Target for IDEAYA Biosciences: $50.44
• High Price Target: $79.00
• Low Price Target: $30.00
• Potential Upside/Downside: +75.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$113.70 million
• Net Margins: N/A
• Pretax Margin: -51.99%
• Return on Equity: -13.94%
• Return on Assets: -12.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.34
• Quick Ratio: 11.34

Sales & Book Value

• Annual Sales: $218.71 million
• Price / Sales: 11.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.67 per share
• Price / Book: 2.46

Miscellaneous

• Outstanding Shares: 87,860,000
• Free Float: 85,664,000
• Market Cap: $2.53 billion
• Optionable: Optionable
• Beta: -0.04